A combination of innovative biochip technology with cutting edge research in molecular allergology has formed the basis for development of ImmunoCAP ISAC - the most advanced in vitro diagnostic test for measurement of specific IgE antiboides to allergen components.
ImmunoCAP ISAC provides the clinician with a broad-spectrum allergen profile on a molecular level.
ImmunoCAP ISAC is the first multiplex in vitro diagnostic tool for the allergy specialist that is based exclusively on allergencomponents.
Currently available standard products for in vivo allergy testing are based on allergen extracts prepared from biological raw materials. They represent natural mixtures of allergenic and non-allergenic molecules that are generally not fully standardized referring to their content of major or minor allergen components.
Today, the increasing availability of allergen components, purified from their natural source or biotechnologically produced as recombinant proteins, marks the beginning of a revolution in allergy diagnosis and leads to a gradual transition towards Molecular Allergology.
Many biological sources contain highly cross-reactive allergen components, for example profilin, which is present in a broad variety of plant pollen and plant derived food. A sensitization towards such a panallergen creates positive test results against numerous allergen extracts. Consequently, when using extract based specific IgE testing it is difficult to identify the correct allergen source when only cross-reactive allergen components are involved.
Availability of specific and cross-reactive marker components creates the platform for more informative diagnostics.
ImmunoCAP ISAC Technology
Based on modern biochip technology, ImmunoCAP ISAC is a miniaturized immunoassay platform that allows for multiplex measurement of specific IgE antibodies to many allergen components using only 20 μl of serum or plasma. Capillary blood sampling can be used, enabling a less invasive procedure for testing young children Purified natural or recombinant allergen components are immobilized on a solid support (biochip). In a two step assay, IgE antibodies from the patient serum bind to the immobilized allergen components. After a short washing step, allergen-bound IgE antibodies are detected by a fluorescence-labeled anti-IgE antibody.
Test results are measured with a biochip scanner and evaluated using proprietary software. ImmunoCAP ISAC is a semiquantitative test and results are reported in ISAC Standardized Units (ISU).
Advantages of ImmunoCAP ISAC Technology
- Multiplex specific IgE measurement to allergen components from over 40 common allergen sources in a single test.
- Using only purified natural or recombinant allergen components.
- Marker allergen components – specific and indicating cross-reactivity.
- Semi-quantitative results based on fluorescence measurements.
- High reliability by intrinsic replicate testing and quality controls.
- 20 μl of patient serum/plasma give complete results.
- Capillary blood sampling enables less invasive procedure for testing young children.
Required Instrumentation
Apart from a biochip scanner ImmunoCAP ISAC requires no special laboratory equipment.
Services
We also offer a service to analyse samples in our laboratory in Copenhagen, Denmark, or via one of our specialised partner laboratories. Please contact us for additional information!
| Product |
Size |
Art. No. |
| ImmunoCAP ISAC |
Assay Kit IgE 20 |
81-1000-01
|